Full-Time

Manager of Customer Success Management

Multiple Teams

Posted on 9/24/2025

Sartorius

Sartorius

5,001-10,000 employees

Laboratory instruments and bioprocess solutions

No salary listed

Germany + 1 more

More locations: Marseille, France

In Person

Category
Sales & Account Management
Required Skills
Risk Management
Requirements
  • University degree in business or equivalent professional background (5+ years) in a customer-facing position
  • Demonstrable experience in leading cross functional projects
  • Experienced in leading and developing teams is essential
  • Proven experience in a customer experience or account management role, or something similar
  • Exceptional communication, negotiation, and influencing skills
  • Proven ability to manage multiple projects efficiently
  • Experience in large-scale transformation programmes
  • Strong planning, execution, and delivery capabilities
  • Proven ability to improve operational efficiency
  • A passion for project management and continuous improvement is essential
  • Strong risk management and contingency planning skills
  • Fluent in English both written and oral
Responsibilities
  • Accountable for the successful management of projects, attending pre-start meetings, devising a strategic programme of works at the start of the contract and continually monitoring progress to ensure projects achieve targets in respect of safety, time, cost, quality and customer satisfaction
  • Build and maintain long-term strategic relationships with key customers
  • Lead and develop a team of customer success professionals
  • Be the point of escalation for customer account sales teams to facilitate communication between internal functions
  • Be the lead for customer related initiatives for the supply of our single use products, collaboration with local involved stakeholders to mitigate risks, fix issues, then feedback to the global function at the Key account
  • Responsibility of monitoring and delivering global and customer KPI’s i.e., OTIF, journey mapping, CX and scorecards
  • Participation as required in regular supply review or business review meetings with internal and external stakeholders to present activities in scope of CSM
  • Design and lead cross-functional customer-oriented project management activities
  • Collaborate with Sales, Product Marketing, and Supply Chain teams to enhance the customer experience
  • To be the coordination between regional Customer Support and global accounts
  • Responsibility of working with customers to limit the impact of lead time changes, understanding customer trends and working with supply chain to find solutions
  • Proactively drive transformation across the Customer Success team and the wider business, promoting change and adoption to maximize the performance of teams and deliver on agreed Revenue Targets, KPI’s and Client SLA’s
  • Review of business processes, systems and team skills with relevant stakeholders to identify, develop and deliver best practice initiatives
  • Lead core project activities such as customer forecasting, VMI, EDI and new business Integration

Sartorius is a global partner in life sciences research and biopharmaceutical manufacturing. It provides laboratories with innovative instruments and consumables for research and quality control, and it offers Bioprocess Solutions focused on single-use systems that help manufacture biotech medicines, vaccines, and cell- and gene- therapies safely, quickly, and cost-effectively. Its products support the full path from drug discovery to commercial manufacturing, with a large worldwide footprint of more than 60 sites and a mission to help more people access better medicines. Sartorius differentiates itself through its broad portfolio spanning lab and bioprocess needs, a strong emphasis on single-use technologies, continuous portfolio expansion via acquisitions, and deep expertise serving pharmaceutical, biotech, and academic customers. Its goal is to simplify progress from research and development to scalable manufacturing so that life-saving medicines can reach patients worldwide.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Simplify Jobs

Simplify's Take

What believers are saying

  • Order intake hit highest Q4 2025 level, book-to-bill above one.
  • Equity ratio reached 48.7% after €1B capital increase in 2024.
  • 6-10% sales growth projected for 2026 with margins above 30%.

What critics are saying

  • Trump tariffs hit German imports; US manufacturing lags by 2027.
  • Danaher's Cytiva bundling steals share from Sartorius platforms.
  • Biotech funding drop 36% in 2024 cuts customer equipment capex.

What makes Sartorius unique

  • Sartorius leads in single-use ultrafilters like Sartocon Slice 50.
  • Ann Arbor $100M Center of Excellence boosts bioanalytics innovation.
  • SIMCA-online software excels in batch process monitoring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Flexible Work Hours

Wellness Program

Professional Development Budget

Company News

The Associated Press
Mar 16th, 2026
Sartorius launches platform to cut CAR-T manufacturing costs by 90% and quadruple output

Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.

Yahoo Finance
Feb 3rd, 2026
Sartorius grows revenue 7.6% to €3.5B with EBITDA margin expanding to 29.7%

Sartorius AG reported strong Q4 2025 results, with revenue growing 7.6% in constant currencies to over €3.5 billion, exceeding full-year guidance. The company's EBITDA margin expanded 170 basis points to 29.7%, whilst underlying net profit increased 18%. The bioprocess solutions division drove growth with 9.5% revenue increase in constant currency, supported by strong double-digit growth in recurring revenue. However, the lab products and services division remained essentially flat at 0.2% growth, facing challenges from unfavorable product mix. Sartorius improved its net debt to EBITDA ratio from 3.96 times to 3.55 times, demonstrating financial discipline. The company set a broad guidance range for 2026, citing macroeconomic volatility. Management noted that US onshoring initiatives are expected to impact revenue from 2027 onwards rather than 2026.

Yahoo Finance
Feb 3rd, 2026
Sartorius Stedim Biotech posts 18% profit growth despite equipment softness, cuts debt ratio to 3.55

Sartorius Stedim Biotech reported strong profit growth for Q4 2025, with revenue increasing 7.6% in constant currencies to over €3.5 billion. The EBITDA margin improved 170 basis points to 29.7%, whilst underlying net profit surged 18%. The bioprocess solutions division led growth at 9.5% in constant currency, driven by double-digit growth in recurring revenue that offset continued equipment softness. Order intake grew faster than sales, with the book-to-bill ratio remaining above one. Free cash flow reached €390 million, though operating cash flow declined to €837 million from €976 million previously. The net debt-to-EBITDA ratio improved from 3.96 to 3.55 times. However, the company faces headwinds from a weaker US dollar and set broad 2026 guidance due to market volatility.

Firmenpresse
Sep 16th, 2025
Repairon secures funding for heart therapy

Repairon GmbH, a German biotech company, has secured a substantial Series A funding for its innovative "heart patch" therapy aimed at treating advanced heart failure. The funding, led by Bioventure Management GmbH and co-invested by Satorius AG, will support the Phase 3 trial and GMP production scaling. The heart patch, made from engineered heart muscle, is applied to damaged heart tissue to restore function. Positive preclinical and Phase 1/2 results were published in Nature.

IT Juzi
Aug 12th, 2025
Nanotein secures $3M strategic investment

Nanotein, a cell therapy developer, has secured a $3 million strategic investment from Sartorius Stedim Biotech.

INACTIVE